1. Home
  2. ARWR vs CHTR Comparison

ARWR vs CHTR Comparison

Compare ARWR & CHTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arrowhead Pharmaceuticals Inc.

ARWR

Arrowhead Pharmaceuticals Inc.

BUY

Current Price

$61.29

Market Cap

12.4B

Sector

Health Care

ML Signal

BUY

Logo Charter Communications Inc. New

CHTR

Charter Communications Inc. New

HOLD

Current Price

$108.26

Market Cap

12.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARWR
CHTR
Founded
2003
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Cable & Other Pay Television Services
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
12.4B
12.5B
IPO Year
2009
1999

Fundamental Metrics

Financial Performance
Metric
ARWR
CHTR
Price
$61.29
$108.26
Analyst Decision
Strong Buy
Hold
Analyst Count
14
22
Target Price
$107.23
★ $175.11
AVG Volume (30 Days)
2.1M
★ 2.6M
Earning Date
11-24-2026
10-30-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 99.80
3.55
EPS
N/A
★ 19.81
Revenue
$16,142,321.00
★ $54,774,000,000.00
Revenue This Year
N/A
$6.03
Revenue Next Year
N/A
$8.15
P/E Ratio
★ N/A
$5.47
Revenue Growth
N/A
★ N/A
52 Week Low
$34.61
$104.91
52 Week High
$95.49
$275.58

Technical Indicators

Market Signals
Indicator
ARWR
CHTR
Relative Strength Index (RSI) 26.63 28.55
Support Level $60.87 N/A
Resistance Level $66.37 $149.20
Average True Range (ATR) 2.53 4.90
MACD -0.36 -1.03
Stochastic Oscillator 6.54 10.17

Price Performance

Historical Comparison
ARWR
CHTR

About ARWR Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.

About CHTR Charter Communications Inc. New

Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 59 million US homes and businesses, around 35% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest US cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (Los Angeles Lakers), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1. Charter plans to acquire cable peer Cox.

Share on Social Networks: